Boehringer Ingelheim is a research-driven company operating worldwide under two divisions: Human Pharmaceuticals and Animal Healthcare. In oncology, Boehringer Ingelheim is mainly focused on three areas: angiogenesis inhibition, EGFR inhibition and cell cycle kinase inhibition.
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Dostarlimab / GSK4057190 / TSR-042 | PD1 | III | Advanced Endometrial Cancer | NCT03981796 | Monoclonal Antibody |
| III | Ovarian Cancer | NCT04679064 | |||
| II | Urothelial Bladder Cancer | NCT04779151 | |||
| II | Gastric Adenocarcinoma | NCT04493060 | |||
| Metastatic Pancreatic Cancer | |||||
| II | Non-Small Cell Lung Cancer | NCT04581824 | |||
| II | Melanoma Stage IV | NCT04139902 | |||
| GSK3359609 | ICOS | III | Relapsed/Metastatic Head and Neck Cancer | NCT04128696 | Monoclonal Antibody |
| Squamous Cell Carcinoma | |||||
| II | R/M Non-small Cell Lung Cancer | NCT03739710 | |||
| Letetresgene autoleucel / GSK 3377794 | NY-ESO-1 | II | Advanced Non Small Cell Lung Cancer | NCT03709706 | Engineered TCR Therapy |
| II | Advanced Synovial Sarcoma | NCT03967223 | |||
| Cobolimab / GSK4069889 / TSR-022 | TIM-3 | II | Advanced Liver Cancer | NCT03680508 | Monoclonal Antibody |
| II | Late Stage Melanoma | NCT04139902 | |||
| GSK3326595 / EPZ015938 | PRMT5 | II | Early Stage Breast Cancer | NCT04676516 | Small Molecule |
| I | Myelodysplastic Syndrome | NCT03614728 | |||
| Acute Myeloid Leukaemia | |||||
| I | Solid Tumors | NCT02783300 | |||
| Non-Hodgkin's Lymphoma | |||||
| GSK3368715 / EPZ019997 | PRMT | I | Solid Tumors | NCT03666988 | Small Molecule |
| Diffuse Large B-cell Lymphoma | |||||
| GSK3537142 / IMCnyeso | NY-ESO, CD3 | I | Advanced Solid Tumors | NCT03515551 | Fusion Protein |
| GSK3745417 | STING | I/II | Advanced Solid Tumors | NCT03843359 | Small Molecule |
| GSK4074386 / TSR-033 | LAG-3 | I | Advanced Solid Tumors | NCT03250832 | Monoclonal Antibody |
| GSK6097608 | CD96 | I | Advanced Solid Tumors | NCT04446351 | Monoclonal Antibody |
| GSK3901961 + GSK3845097 | NY-ESO-1, LAGE-1a | I | Solid Tumors | NCT04526509 | Engineered TCR Therapy |
| Advanced Synovial Sarcoma | |||||
| Advanced Non Small Cell Lung Cancer |
Boehringer Ingelheim Active Oncology Pipeline Drug Description
- Xentuzumab is a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation.
- Ezabenlimab is a humanized programmed cell death protein-1 (PD-1)-targeting monoclonal antibody (mAb) that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which can inactivate T cells.1 In doing so, ezabenlimab allows T cells to remain active against tumor cells.
- BI 894999 is an oral, potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of bromodomain (BRD)-containing proteins.
- BI 3011441 (LNP3794) is a small-molecule allosteric inhibitor that binds adjacent to the ATP pocket of MEK, resulting in inhibition of MEK kinase activity.
- BI 765063 is a first-in-class myeloid checkpoint inhibitor.1 By blocking the interaction between myeloid cell-surface molecule signal-regulatory protein alpha (SIRPα) and cluster of differentiation 47 (CD47), SIRPα inhibits suppression of the innate immune system and restores the immune functions of myeloid cells in the tumor microenvironment.
- BI 891065 is a mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins), with potential antineoplastic activity. Upon administration, Smac mimetic BI 891065 targets and binds to the Smac binding groove on IAPs, including the caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting certain caspases.
- BI 1701963 is a first-in-class protein::protein interaction inhibitor that binds the Son of sevenless homolog 1 (SOS1), thereby inhibiting the interaction and activation of the key cancer driver Kirsten rat sarcoma (KRAS) proteins.
- BI 907828 is an oral, small-molecule murine double minute 2 (MDM2)-p53 antagonist that may promote p53-mediated cell-cycle arrest and apoptosis.
- Miptenalimab (formerly BI 754111) is a humanised IgG4 anti-lymphocyte-activation gene 3 (LAG3) monoclonal antibody
- BI 905677 is a humanized biparatopic nanobody® comprising two blocking domains for lipoprotein receptor-related proteins (LRP) 5 and 6, which are co-receptors for Frizzled, the Wnt ligand receptor. BI
- 905677 binds to LRP5 and LRP6 with high affinity, thereby blocking the binding of Wnt to LRP5/6 and Frizzled, and inhibiting Wnt ligand-/β-catenin-driven cancer proliferation, survival and immune escape.
- BI 905711 is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells.
- BI 836880 is a humanized bispecific nanobody® comprising blocking domains for vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). BI 836880 is a potent and selective inhibitor of VEGF and Ang2.
- BI 764532 is a delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific antibody functions as a T-cell engager, acting as a bridge that selectively directs the activity of cytolytic T cells to DLL3-expressing tumor cells.
Page 2 of 2
